Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Stephen K. Van Den Eeden

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5599-8387; OpenAlex author ID A5023847764; NIH RePORTER profile ID 6408921. Sources: OpenAlex.

Their work

Papers
20
Trials
0
Grants
1
Labs led
1
Collaborators
95
Papers, trials and grants by year

2013: 2 papers · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: 1 paper, 1 grant · 2020: 2 papers · 2021: 3 papers · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: none · 2026: 6 papers

Papers 20

  1. Towards early detection of pancreatic cancer: The current status of cohort studies by the Diabetes-Pancreatic Ductal AdenoCarcinoma Working Group. Co-author DOI 10.1016/j.pan.2026.04.020↗
  2. Polygenic scores for risk of pancreatic ductal adenocarcinoma: evaluation of novel and published models. Co-author DOI 10.1038/s41698-026-01479-x↗
  3. Risk of Pancreatic Cancer in Glycemically Defined New-Onset Diabetes: A Prospective Cohort Study. Co-author DOI 10.1053/j.gastro.2025.06.025↗
  4. Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis. Co-author DOI 10.1093/jnci/djaf308↗
  5. Adult Chronic Pancreatitis Working Group: Goals, Accomplishments and the Path Ahead. A Report From the Consortium for the Study of Chronic Pancreatitis, Diabet… Co-author DOI 10.1097/mpa.0000000000002657↗
  6. Assessment of impending pancreatic cancer in a cohort of new onset diabetes on basis of biomarker trajectory Co-author DOI 10.64898/2026.08.06.26359908↗
  7. Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer. Co-author DOI 10.1038/s41467-023-40024-3↗
  8. Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization. Co-author DOI 10.1158/1055-9965.epi-23-0453↗
  9. The age-dependent association of risk factors with pancreatic cancer. Co-author DOI 10.1016/j.annonc.2022.03.276↗
  10. A 584 bp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer. Co-author DOI 10.1016/j.ajhg.2021.09.002↗
  11. Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. Co-author DOI 10.1093/ajcn/nqab217↗
  12. Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Co-author DOI 10.1158/0008-5472.can-20-3267↗
  13. A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djz246↗
  14. Associations between Genetically Predicted Blood Protein Biomarkers and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-20-0091↗
  15. Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djy155↗
  16. A Prospective Study to Establish a New-Onset Diabetes Cohort: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001169↗
  17. PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies: Rationale and Study Design for PROCEED From the Consortium for the … Co-author DOI 10.1097/mpa.0000000000001170↗
  18. Correction: vitamin d metabolic pathway genes and pancreatic cancer risk. Co-author DOI 10.1371/journal.pone.0129983↗
  19. Family history of diabetes and pancreatic cancer as risk factors for pancreatic cancer: the PACIFIC study. Co-author DOI 10.1158/1055-9965.epi-13-0518↗
  20. An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population. Co-author DOI 10.1371/journal.pone.0072311↗

Grants 1

  1. Chronic Pancreatitis, Diabetes and Pancreatic Cancer: A Prospective Approach U01DK108332↗

Closest collaborators

The 25 strongest of 95 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Phil A. Hart · 6 shared papers, 2018–2026 · strength 1.05
  2. Suresh T. Chari · 5 shared papers, 2018–2026 · strength 0.82
  3. Anirban Maitra · 4 shared papers, 2018–2026 · strength 0.76
  4. Santhi Swaroop Vege · 3 shared papers, 2026 · strength 0.69
  5. Stephen Jacob Pandol · 4 shared papers, 2018–2026 · strength 0.60
  6. Walter Gwang-Up Park · 4 shared papers, 2018–2026 · strength 0.60
  7. Jo Ann Rinaudo · 4 shared papers, 2018–2026 · strength 0.59
  8. Ziding Feng · 4 shared papers, 2018–2026 · strength 0.58
  9. Christopher E Forsmark · 3 shared papers, 2018–2026 · strength 0.53
  10. Evan L Fogel · 3 shared papers, 2018–2026 · strength 0.53
  11. William E Fisher · 2 shared papers, 2026 · strength 0.46
  12. Bechien U. Wu · 2 shared papers, 2026 · strength 0.45
  13. Steven J. Hughes · 3 shared papers, 2018–2026 · strength 0.37
  14. José Serrano · 3 shared papers, 2018–2026 · strength 0.36
  15. Randall E. Brand · 2 shared papers, 2018–2026 · strength 0.31
  16. Temel Tirkes · 2 shared papers, 2018–2026 · strength 0.29
  17. Mark D. Topazian · 2 shared papers, 2018–2026 · strength 0.29
  18. Dhiraj Yadav · 2 shared papers, 2018–2026 · strength 0.29
  19. Darwin Lewis Conwell · 2 shared papers, 2018–2026 · strength 0.29
  20. Bechien Wu · 1 shared paper, 2026 · strength 0.24
  21. Matthew R. Young · 1 shared paper, 2026 · strength 0.23
  22. Ehsan Irajizad · 1 shared paper, 2026 · strength 0.23
  23. Jody V. Vykoukal · 1 shared paper, 2026 · strength 0.23
  24. Johannes Francois Fahrmann · 1 shared paper, 2026 · strength 0.23
  25. Samir Hanash · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.